Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2459/JCM.0000000000001192 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Studies showed significant physical improvement after starting elexacaftor/tezacaftor/ivacaftor (ETI). However, some patients reported new mental health symptoms.
Aim: This study explores the impact of ETI on end-stage cystic fibrosis patients, focusing on mental health.
Abatacept dose-finding phase II triaL for immune checkpoint inhibitors myocarditis (ACHLYS) trial design.
Arch Cardiovasc Dis
December 2024
Department of pharmacology, Sorbonne Université, Inserm, CIC-1901, AP-HP, Hôpital Pitié-Salpêtrière, 75013 Paris, France.
Background: Immune checkpoint inhibitor (ICI)-induced myocarditis is a life-threatening adverse drug reaction. Abatacept (a CTLA-4-immunoglobulin fusion protein) has been proposed as a compassionate-use treatment for ICI myocarditis (in combination with corticosteroids and ruxolitinib) but no clinical trial has yet been performed. The abatacept dose can be adjusted using real-time assessment of its target, the CD86 receptor occupancy on circulating monocytes (CD86RO).
View Article and Find Full Text PDFPerspectives on Diversion of Medications From Safer Opioid Supply Programs.
JAMA Netw Open
December 2024
School of Social Work, University of Windsor, Windsor, Ontario, Canada.
Importance: Safer supply programs were implemented in Canada to provide pharmaceutical-grade alternatives to the toxic unregulated drug supply. While research shows clinical benefits and reduced overdose mortality among safer supply patients, medication diversion remains a concern.
Objective: To examine provider (prescribing clinicians and allied health professionals) and patient perspectives on diversion of opioids prescribed in safer supply programs.
Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel disease.
World J Gastroenterol
December 2024
Department of Gastroenterology, St. Paul's Hospital, Vancouver V6Z 1Y6, British Columbia, Canada.
Background: Over the last decade, the treatment options for inflammatory bowel disease (IBD) have significantly progressed with the emergence of new medications designed to target various immune pathways and mitigate inflammation. Adalimumab (ADA) is a tumor necrosis factor alpha antagonist and stands as an effective treatment for IBD. In April 2021, the province of British Columbia implemented a mandatory non-medical switch policy of the ADA originator Humira to ADA biosimilars.
View Article and Find Full Text PDFMotivations for and perspectives of medication diversion among clients of a safer opioid supply program in Toronto, Canada.
Int J Drug Policy
December 2024
Centre on Drug Policy Evaluation, MAP Centre for Urban Health Solutions, St. Michael's Hospital, Toronto, ON, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. Electronic address:
Article Synopsis
- - The study aimed to understand the experiences and perspectives of clients involved in safer opioid supply programs in Toronto, focusing on the diversion of medications, which is a concern in such programs.
- - Researchers conducted interviews with 25 clients over several months, identifying key themes such as compassionate sharing, survival needs, high demand for safer alternatives, and issues of coercion in medication diversion.
- - The findings reveal complex motivations behind medication diversion, suggesting that future policies should tackle the underlying causes and improve access to services and diverse medication needs for clients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!